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ABSTRACT Transgenic mice lacking an intact P2-
microglobulin (J32m) gene fail to express major histocompati-
bility complex (MHC) class I proteins on the cell surface and,
as a result, are virtually devoid of CD4- CD8+ lymphocytes.
These animals provide a unique model system for directly
assessing the role of CD8+ lymphocytes in the modulation of
viral infection in vivo. P2m_ CD8- mice and their normal
littermates were inoculated at the base of the tail with the WR
strain of vaccinia virus and monitored for serum antibody and
lesion formation. Both groups developed similar lesions in
response to a broad virus dose range, and all animals had
completely recovered by day 28 after inoculation. Isotype-
specifi immunogibulin levels were determined for each animal
on day 7 and day 14 after primary inoculation, and again 7 days
after a virus challenge. The virus-specific IgG1, IgG2a, and
IgG2b levels were signifcantly different in the (2m-/- group
(20-, 9-, and 30-fold lower, respectively, on day 7 after chal-
lenge) compared with the f2m+ /- group. Virus-specific serum
IgM levels for both groups remained similar throughout the
experiment. In a separate experiment, 32m-/- mice were
immunized with a nonviral antigen, 2,4,6-trinitrophenyl-
conjugated keyhole limpet hemocyanin, and both total and
antigen-specific isotype-specific immunoglobulin titers were de-
termined. Total IgG1, IgG2a, IgG2b, and IgG3 tended to be
iower overall in the f2m-/- mice compared with j82m+/-
littermates. In contrast, total and antigen-specific IgE titers were
similar in the two groups. These data indicate that CD81
lymphocytes are not required to clear high doses of vaccinia
virs, and they suggest that f21m/- mice are less efficient at
antigen-specific IgG production than their(3m+/- littermates.
Cytolytic T lymphocytes (CTL) have been reported to play
an important role in host modulation of viral infections.
Virus-specific CD4- CD8+ CTL can be detected prior to
neutralizing antibody, as early as 4 days after infection with
viruses such as ectromelia or influenza (1, 2). It is thought
that CTL are able to eliminate virally infected host cells prior
to the release of progeny virus particles, resulting in effective
limitation or early clearance ofthe viral infection (3, 4). CD8+
CTL recognize infected cells through the T-cell receptor,
which binds to virus-specific peptides displayed on the cell
surface in conjunction with major histocompatibility complex
(MHC) class I proteins (5, 6). Class I MHC molecules on the
cell surface are noncovalently associated with a small P2-
microglobulin (f32m) peptide (7, 8). In the absence of expres-
sion of f2m, the transport of class I MHC molecules is
arrested in the endoplasmic reticulum and the MHC mole-
cules are not available for cell surface expression and antigen
presentation (9, 10). Recently, stable murine lines carrying a
disrupted f32m gene have been developed (11, 12). These mice
appear normal; however, they lack detectable MHC class I
molecules on their cell surfaces, and they are almost com-
pletely devoid of CD4- CD8+ lymphocytes. These mice thus
provide an excellent opportunity to examine the role ofCD81
T cells and class I MHC-mediated antigen presentation in the
modulation of virus infection.
Vaccinia virus (VV) is a prototypic member of the poxvirus
family. These viruses typically elicit a strong cell-mediated
immune response in the infected host. The WR strain ofVV
is a neurovirulent strain that was isolated by repeated passage
in suckling mouse brain (13). The LD50 varies with the route
of administration but is greater than 109 plaque-forming units
(pfu) when given intradermally (i.d.) in normal mice (14).
Lesions, the size of which can vary with the strain of mouse
immunized, may appear at the site of inoculation. Nude mice
inoculated with as few as 10 pfu of VV develop generalized
vaccinia and typically die within 28 days (M.K.S., unpub-
lished observations).
We have examined the role ofCD8+ cells in the modulation
of VV infection by using f32m-/- CD8- transgenic mice.
32m-/- mice and their normal littermates were examined for
lesion formation in response to a broad virus dose range and
were serologically monitored for virus-specific isotype-
specific antibody production. In this paper, we report that (i)
832m-/- mice survived infection with up to 5 x 108 pfu ofVV;
(ii) the course of infection in ,2m-/- mice appeared indis-
tinguishable from that seen in I32m+/- littermates; and (iii)
132m-/- mice produced less virus-specific IgG antibodies
after infection than did their 32m+/- littermates, although
both groups produced similar levels of virus-specific IgM.
We compared the antibody response of these mice to the
response to a nonviral soluble antigen, 2,4,6-trinitrophenyl-
conjugated keyhole limpet hemocyanin (TNP-KLH). This
antigen typically elicits strong secondary IgG1 and IgE
responses and provides an alternative method for examining
an antigen-specific immunoglobulin response (15). These
experiments showed that P32m-/- mice produced somewhat
less TNP-KLH-specific IgG1 than did their normal litter-
mates, but both groups produced equivalent levels of TNP-
KLH-specific IgE.
MATERIALS AND METHODS
Animals and Antigens. 32m-deficient mice were derived by
the introduction of E1422A embryonic stem cells carrying a
disrupted 182m gene into C57BL/6 mice (11). Chimeric off-
Abbreviations: CTL, cytolytic T lymphocytes; MHC, major histo-
compatibility complex; Hem, 192-microglobulin; VV, vaccinia virus;
pfu, plaque-forming units; TNP-KLH, 2,4,6-trinitrophenyl-
conjugated keyhole limpet hemocyanin; mAb, monoclonal antibody;
sIgM, surface IgM.
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spring were selected on the basis of coat color and then
backcrossed to C57BL/6 mice. The resulting heterozygous
offspring were mated to give the F2 animals used in these
experiments. Southern blot analysis of tail DNA was per-
formed on individual animals to determine genotype. The WR
strain of VV was purchased from the American Type Culture
Collection and plaque purified as described (16). TNP-KLH
was precipitated with alum under pyrogen-free conditions.
Intraperitoneal injections were performed with 1 ,ug of TNP-
KLH in a final volume of 200 ILI.
ELISAs. VV-specific ELISAs were performed essentially
as described (17), using horseradish peroxidase-conjugated
isotype-specific antibodies (Southern Biotechnology Associ-
ates, Birmingham, AL). Antiviral antibody titers are reported
as half-maximal units per ml and are derived as follows:
Immune "standard" serum from a single heterozygous
832m+/- mouse was used to determine a maximum possible
OD value for each isotype. A titration of this standard serum
was performed for the appropriate isotype-specific reagent
on each plate to control for plate-to-plate variation. Half-
maximal values are arbitrary units equivalent to the amount
of antibody present in the dilution of test serum required to
give an OD reading equal to one-half the maximal OD value
for the standard serum. All titrations were performed in
duplicate and curves were generated from the average OD
value per point. Half-maximal values were calculated by
using the BIOASSAY program. Full documentation of the
BIOASSAY program set can be found in Bioassay Analysis
Program Documentation Protocol (Immunex: August 1990).
Calculations consist of eliminating unusable data points,
calculating fractional percentages of assay maxima, logit
transforming data, performing least-squares line fits, and
plotting as dilution of serum vs. OD. The lower limit of
detectability in these assays was 2.5 units/ml. Serum samples
with a half-maximal value less than 2.5 units/ml were as-
signed a value of zero for purposes of statistical analysis.
Student's t tests were performed by using STATWORKS ver-
sion 1.2, 1985 (Cricket Software, Philadelphia). Total isotype
levels were determined by an isotype-specific sandwich
ELISA as described previously (18). Primary and secondary
anti-TNP IgG1 and IgE levels were determined by a modified
sandwich ELISA method. Plates were coated with anti-
murine IgG1 or IgE antibodies, blocked with nonfat dry milk,
and incubated with test serum samples. Bovine gamma
globulin was 2,4,6-trinitrophenylated and biotinylated as
described (19, 20) and added to each well, followed by
horseradish peroxidase-conjugated streptavidin. Wells were
developed with peroxidase substrate and analyzed as de-
scribed above. Dinitrophenyl-specific myeloma antibodies
[TIB 191 (IgGi) and A3B1 (IgE)] were used as standards to
determine antigen-specific IgG1 and IgE levels.
Immunofluorescent Staining and Flow Cytometry. The fol-
lowing monoclonal antibodies (mAbs) were used in these
studies: 2A3.6B2 mAb, which specifically recognizes Ly5/
B220 antigen on B-lineage cells (21); 25-9-17 mAb, which
recognizes I-Ab (22); 28-8-8 mAb, which recognizes Kb, Db
(22); 2.4G2 mAb, which recognizes the Fcy receptor (23);
53-12.7 mAb, which recognizes murine CD8 (24); and GK1.5
mAb, which recognizes murine CD4 (25). For assessment of
the expression of B220 and surface IgM (sIgM) on lymph
node and spleen cells, cells were incubated with phycoeryth-
rin (PE)-conjugated goat anti-mouse IgM (Southern Biotech-
nology Associates) and fluorescein isothiocyanate (FITC)-
conjugated anti-B220. To assess the expression of CD4 and
CD8, cells were preincubated with 2.4G2 mAb, washed, and
incubated with PE-conjugated anti-CD4 and FITC-conju-
gated anti-CD8 (Becton Dickinson). To assess the expression
of class I or II MHC antigens, cells were incubated with either
28-8-8 mAb or 25-9-17 mAb, washed, and incubated with
FITC-conjugated F(ab')2 fragment of goat antibody specific
for the Fc fragment of mouse IgG (Cappel Laboratories).
Analysis was performed on a FACScan flow cytometer
(Becton Dickinson). Background staining was assessed by
incubating the cells with isotype-matched antibodies of irrel-
evant specificity followed by the second step antibody or by
staining with FITC- or PE-conjugated mouse IgG1 (Becton
Dickinson). For two-color analysis, cells stained with each
antibody alone were first analyzed to determine the degree of
spectral overlap.
RESULTS
Lesion Formation After Inoculation with W. Homozygous
82m-/- mice and their normal heterozygous P2m+/- litter-
mates were inoculated i.d. at the base of the tail with 5 x 102,
5 x 105, or 5 x 108 pfu of VV. Three mice of each genotype
were used for each dose group. Animals were weighed twice
weekly and monitored every other day for lesion formation.
Lesions were scored on a 1+ to 4+ scale, with 1+ including
lesion diameters of up to 2 mm, erythema, or traces of vesicle
formation, and 4+ including lesions greater than 1 cm, which
were fully vesicular and weeping.
At the site of inoculation all animals formed lesions, the
size and severity of which correlated with the dose of virus
administered. Mice in the low-dose group developed detect-
able lesions between days 10 and 12, which peaked by day 14
and were completely healed by day 28. Lesions typically
ranged from 1+ to 2+ on day 14 with no difference apparent
between the animals lacking CD8+ lymphocytes and their
normal littermates. Animals receiving the midrange dose
typically developed lesions by day 7, which peaked from day
12 to day 14 and were completely healed by day 28. Lesions
ranged from 2+ to 3+ on day 14, again with no difference
between the two genotypes at the level of either lesion size
or progression. Animals that were given the highest dose (5
x 108 pfu) began developing lesions by day 4 or 5, and by day
14 all animals in both 32m-/- and ,32m+/- groups had 4+
lesions, some of which had spread to cover most of the tail.
All lesions in both groups had completely healed by day 28,
although these animals sustained permanent scar tissue on
the tail. Interestingly, animals of either genotype in all dose
groups experienced no spread of viral lesions to parts of the
body other than the tail. No lesions were detected even at
peak times on the feet, face, eyes, or oral cavity. At the onset
of the study, animals ranged in weight between 20 and 30.1
g. Over the 28-day course of the experiment, all animals
experienced weight gains consistent with normal growth in
age-matched uninfected mice.
Serum samples were collected on day 0 prior to inocula-
tion, and again on day 7 and day 14. An ELISA was used to
determine virus-specific IgM and IgG titers for each animal.
All animals were seronegative for VV antibodies at the onset
and all developed detectable virus-specific antibodies by day
7. As expected, the levels of IgM and IgG correlated with the
amount of virus administered (data not shown). However, it
appeared that for each dose of virus administered, the IgG
response was less vigorous in the 32mW-/ CD8- mice than
in their littermates. To document this finding more carefully,
the experiment was repeated on a broader scale.
Antibody Response of (32m/- and P22m+/- Mice to W.
Ten heterozygous 132m+/- and eight homozygous p2m-/-
mice were administered 5 x 104 pfu i.d. at the base of the tail.
On the basis of the previous study, this dose of virus could
be expected to give a vigorous immune response without
severe lesion formation. On day 21 after inoculation, animals
were challenged intraperitoneally (i.p.) with 108 pfu of VV.
Serum samples were taken on day 0 prior to inoculation, then
on day 7, day 14, and day 28.
After primary inoculation, both p2mj- and 62m+/- mice
developed lesions ranging from 1+ to 2+ in size, and all
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Table 1. Isotype-specific serum antibody response to VV in P3m-/- CD8- mice and their normal littermates
Anti-VV titer
Day 7 Day 14 Day 28
Mice IgM IgM IgG IgG1 IgG2a lgG2b IgM IgG IgG1 IgG2a IgG2b IgG3
I32m+/- 3 425 1592 235 584 676 184 2206 1249 1817 474 37
32m-/- 3 762 301 14 175 159 242 423 59 197 16 <2.5
P 0.911 0.237 <0.001 <0.001 0.232 0.003 0.578 <0.001 <0.001 0.042 0.001 <0.001
Ten heterozygous 132m+/- mice and eight homozygous p2m-/- mice were inoculated on day 0 as described in the text. On day 21, animals
were boosted with 108 pfu of VV i.p. Serum samples were collected on the indicated days and half-maximal ELISA values were determined.
The lower limit of detectability in these assays was 2.5 units/ml. The values listed represent geometric means of the half-maximal value for each
isotype within a genotypic group. P values for homozygous vs. heterozygous mice were determined by using Student's t test on the
log-transformed data; P values <0.05 are considered significant.
lesions resolved by day 28. No morbidity or generalized
lesions were observed in any mice after the i.p. challenge.
Virus-specific isotype-specific ELISA was performed with
serum obtained from individual animals. The results of these
assays are summarized in Table 1, where the values listed
represent the geometric mean of the half-maximal serum
antibody titers (see Materials and Methods) for a given
isotype within a genotypic group.
Virus-specific IgM titers were not significantly different
between the 132m-/- and I32m+/- mice at any time of testing
during the course of the experiment. Virus-specific serum
IgM levels were increased in both groups on day 14 compared
with day 7, but they did not significantly increase after the i.p.
challenge. In contrast, virus-specific IgG titers were greater
in f2m+m/- normal mice on day 14 than in f32m-/- transgenic
mice. After the challenge (day 28), all IgG titers increased in
all animals, and the disparity between the IgG isotype titer in
82m-/- and 32m+/- mice was even more pronounced. At
this time, the IgG1, IgG2a, and IgG2b titers differed by 20-,
9-, and 30-fold, respectively. The magnitude of difference in
IgG3 levels is difficult to calculate accurately, as 32m-/-
frequently had nondetectable levels of this isotype. All
f32m+/- mice, however, did respond to inoculation by pro-
ducing detectable levels of IgG3.
Table 1 also lists Student's t test P values comparing
,8m+/- and 32m_/- titers for each isotype at day 14 and day
28. At day 28, all IgG isotype levels were significantly
different in the ,2m-/- and 182m+/- groups at the 0.05 level.
Scatter plots depicting the serologic data for individual
animals on day 28 are shown in Fig. 1. The IgG titers within



















in the I2m+/- group. This was also seen in the titers
determined on day 14 (data not shown).
Humoral Immune Response to TNP-KLH. The results de-
scribed above suggested that expression of class I molecules
may be involved in the development of strong anti-viral
antibody responses. We sought to determine whether this
requirement extends to other antigens by immunizing mice
with a nonviral antigen (TNP-KLH) and measuring the
antigen-specific isotype levels in serum. TNP-KLH is a
hapten-carrier conjugate that has been shown to elicit strong
T-cell-dependent antibody responses in mice, particularly of
the IgE and IgG1 isotypes (15). Mice were immunized with
TNP-KLH on day 0 and boosted on day 21, and primary (day
9) and secondary (day 26) anti-TNP responses were measured
by ELISA analysis of sera. Fig. 2 A and B compares the total
and anti-TNP-specific IgE levels in sera from 9 f2m-/- and
10 pfm+/- mice. Mice in both groups mounted equivalent
secondary anti-TNP IgE responses. Comparison of total and
anti-TNP IgE levels indicates that the majority of the total
IgE present was antigen-specific, which is typical of anti-
TNP IgE responses in normal mice. It is noteworthy that the
ranges of secondary anti-TNP IgE responses for P2m-/-
(0.88-13.37 ,ug/ml) and P2m+/- (0.033-20.57 ,ug/ml) mice
were quite broad. The animals used in this study represent a
diverse genetic background, being an F2 generation outbred
from 129/Ola x C57BL/6 (see Materials and Methods). This
diversity may account for the wide range of antigen-specific
IgE responses in the mice. Nevertheless, the results strongly















FIG. 1. Scatter plots depicting VV-specific serum antibody re-
sponses from individual 132m-/- and 132m+/- mice on day 28. Mice
were inoculated as described in the text. Isotype-specific ELISA was
performed on serum samples taken 7 days after challenge. The


























FIG. 2. Serum anti-TNP and total IgE and IgG1 secondary
responses in mice immunized with TNP-KLH. Day 26 sera (5 days
after secondary immunization) were assayed for total (A and C) or
TNP-specific (B and D) immunoglobulin levels by isotype-specific
sandwich ELISAs. Each point represents IgE (A and B) or IgG1 (C
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Table 2. Total serum isotype levels in I32m+/- and 32m-/- mice before and after immunization and challenge with TNP-KLH
Isotype concentration, ,ug/ml
Sera Mice IgE IgG1 IgG2a IgG2b IgG3 IgM
Preimmune 32m-/- <0.01 11.89 x/. 1.31 4.08 x/. 1.33 18.75 x/. 1.30 15.60 x/. 1.37 1199 x/. 1.15
P32M+/- <0.01 92.33 x/. 1.24 13.40 x/. 1.34 58.28 x/. 1.32 83.47 x/. 1.25 776 x/. 1.23
Primary P82m-/- 0.04 x/. 1.56 21.97 x/÷ 1.31 5.94 x/÷ 1.42 29.41 x/÷ 1.25 29.54 x/÷ 1.43 1662 x/÷ 1.12
I32m+/- 0.02 x/. 1.40 116.30 x/. 1.21 18.40 x/. 1.36 88.76 x/. 1.36 139.66 x/. 1.21 1202 x/ 1.19
Secondary 832m/- 6.14 x/. 1.38 106.57 x/÷ 1.28 5.69 x/÷ 1.38 39.93 x/. 1.40 40.63 x/. 1.34 1948 x/. 1.16
f32m+/- 3.58 x/. 1.87 239.78 x/. 1.36 19.70 x/. 1.31 85.99 x/. 1.38 176.67 x/. 1.28 1542 x/. 1.17
Values are reported as geometric means x/. SEM of total isotype in sera from 62m+/- (n = 10) and 32m-/- (n = 9) mice. Preimmune,
primary, and secondary bleedings were performed on day 0, day 9, and day 26, respectively, after primary immunization with TNP-KLH.
has a major influence on the generation of an antigen-specific
IgE response.
Serum IgG1 was also measured in both groups of mice. The
results in Fig. 2C show that total serum IgG1 levels after
challenge with TNP-KLH tended to be lower in 32m-/-
mice than in 02m+/- mice. The anti-TNP IgG1 results (Fig.
2D) are less conclusive due to the presence of two high
responders in the P2m+/- group. If these two outlier values
are disregarded, the IgG1 anti-TNP levels for the two groups
are similar. These findings suggest that class I antigen-
deficient mice are capable ofmounting a normal TNP-specific
IgG1 response, although interpretation of these results is
hampered by the wide range of values that were observed for
individual mice.
The levels of total serum isotypes in preimmune, primary,
and secondary sera are listed in Table 2. The preimmune sera
results indicate that the ,2m-/- mice had lower total IgG1,
IgG2a, IgG2b, and IgG3 than littermate controls. Moreover,
the isotype levels in 82m-/- mice remain lower than those
in ,82m+/- mice throughout the course of the immunization
period. Interestingly, examination of the difference in IgG1
levels within the two groups indicates that the 82m-/-
animals exhibit a greater than 9-fold increase in secondary
IgG1 levels compared with preimmunization levels, while
/32m+/- showed a less than 3-fold increase. In contrast to the
IgG results, there did not appear to be a difference between
groups in the ability to produce IgE or IgM. Thus, /32m/-
animals can mount a humoral response to soluble antigen, but
they clearly exhibit a deficiency in levels of IgG subclass
production.
Phenotypic Analysis of Lymphoid Tissue. Spleen and mes-
enteric lymph nodes from normal C56BL/6, ,2m+/-, and
P2m-/- mice were assessed for the numbers of cells ex-
pressing CD4, CD8, and B220/sIgM by immunofluorescent
staining and flow cytometric analysis. As seen in Table 3,
832m-/- mice had a significantly greater total number of
spleen cells than either the 92m+/- mice or C57BL/6 mice.
The increased splenic cellularity was due to greater numbers
of CD4+ cells, sIgM+ cells, and cells negative for both of
these markers (null cells). These data indicate that the
decrease of IgG in the 2m-/- homozygotes is not a result
of a diminished number of B220+/sIgM+ precursor cells.
Interestingly, analysis of the mesenteric lymph nodes from
these same mice revealed no difference in total cellularity or
in the numbers of CD4+, sIgM+, or null cells between the
groups (data not shown).
DISCUSSION
The cell-mediated component of the immune system is con-
sidered to be of equal if not greater importance than humoral
immunity in the modulation of pathogenesis of many infec-
tious diseases. Studies performed with virus-infected mice
have led to the widely accepted notion that CD8+ CTL are the
primary mediators of immunity against viruses such as pox-
viruses and influenza. Virus-specific CD8+ CTL are readily
isolated from animals infected with these viruses, and in vitro
studies have clearly identified viral proteins that are recog-
nized by CTL in association with class I MHC molecules on
the surface of infected cells (refs. 26 and 27; for a review, see
ref. 28). Adoptive transfer experiments, in which lethal
infections can be abrogated by infusion ofCTL in the absence
of neutralizing antibody, provide even more compelling ev-
idence for a critical role ofCTL in the clearance of poxviruses
(29, 30).
In the case of VV, the evidence for the importance of
cell-mediated immunity in limitation and recovery from dis-
ease comes primarily from data gathered during the years of
widespread immunization against smallpox in humans. Pa-
tients with known cell-mediated immune dysfunction typi-
cally developed severe generalized rashes after immunization
(31), which was characteristic of progressive vaccinia (vac-
cinia necrosum). In mice, the evidence for the importance of
CTL in immunity is indirect because VV is not typically lethal
unless administered intracranially. To test directly the role of
CD8+ CTL in the clearance ofVV infection, we investigated
the progression ofVV infection in mice lacking CD8+ T cells.
/32m-/- mice and their normal littermates were inoculated
with various doses of VV. Animals of both genotypes devel-
oped similar lesions, the severity of which were dose-
dependent. All animals survived inoculation, even at doses
exceeding 108 pfu, and experienced little if any outward signs
of viremia or illness. These results demonstrate directly that
CD8+ CTL are not required for the clearance ofVV in these
mice. Although the CD8+ cells are likely to play an important
role in the modulation of viral infections in a normal animal,
it is clear that the immune system provides sufficient overlap
to protect ,2m-/- from VV infection under these conditions.
Table 3. Phenotypic analysis of splenic lymphocyte populations
Cells x 10-6
Mice Total cellularity CD4+ CD8- CD4- CD8+ B220+/sIgM+ Null
C57BL/6 133.8 ± 8.2 17.3 ± 2.4 12.8 ± 1.8 81.9 ± 6.7 20.8 ± 2.6
P82m+/- 152.2 ± 13.1 15.1 ± 1.5 11.1 ± 2.6 103.8 ± 11.3 21.7 ± 1.1
32m-/- 213.7 ± 15.4 24.2 ± 3.4 0.8 ± 0.8 138.8 + 15.1 49.6 ± 9.5
The data are the arithmetic mean ± SEM of 5 individually assayed mice. The numbers of CD4+,
CD8+, and sIgM+ cells are the product of the percent positively staining cells and the total cellularity
of the spleen. The numbers of null cells are the sum of the numbers of CD4+, CD8+, sIgM+ cells
subtracted from the total cellularity.
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The exact nature of the effector mechanisms is not known.
One explanation might be that other cytolytic cells such as
CD4+ CTL and/or natural killer (NK) cells play a prominent
role in viral clearance in the absence of CD8+ CTL. Indeed,
phenotypic analysis of splenic lymphoid cells of 82m-/-
mice (Table 3) showed increased CD41 and null cell subsets
compared with their littermate controls. Consistent with this
hypothesis, Karupiah et al. (32) have shown that nude mice
infected with a recombinant VV expressing interleukin 2
survive infection and exhibit elevated NK cell activity. NK
activity has also been shown to be important in the resistance
of mice to a variety of herpesvirus infections (33-36) and
perhaps is critical to resistance to herpesvirus infection in
humans (37).
An unexpected finding regarding the ability of .82m-/-
mice to mount an antibody response to VV emerged from
these studies. Virus-specific antibody titers were examined
by ELISA after inoculation and virus challenge. The levels of
virus-specific IgG were significantly lower in the P2m-/-
group than in their normal littermates, while serum IgM
levels were similar. To investigate whether this difference
was limited to a response to viral antigens, a similar exper-
iment was performed in which H2m-/- and their normal
littermates were immunized with a nonviral hapten carrier,
TNP-KLH, which elicits strong IgE and IgG1 responses in
normal mice. In this experiment, amounts of antigen-specific
IgE in the serum of H2m-/- and P2m+/- mice were similar;
a large degree of variability in the IgG1 response made results
for this subclass difficult to interpret. However, examination
of total serum antibody (non-antigen-specific) (Table 2) in-
dicated that total IgM and IgE levels were similar in the two
groups but that total IgG levels were lower in p32m-/- mice
than in «m+/- controls. This was true for both preimmune
sera and sera taken after immunization or challenge and
applied to all IgG isotypes. When these data are considered
together with data on virus-specific IgG in ,82m-/- mice, it
appears that mice lacking h2m are less efficient in the
generation of IgG antibody than their normal littermates and
that class I antigen expression is not required for the gener-
ation of an antigen-specific IgE response.
The mechanism responsible for diminished production of
certain IgG isotypes in f32m-/- mice is unclear. The numbers
of B cells as defined by B220 and sIgM were comparable
between H2m/- mice and their normal littermates, Given
the role of cytokines in class switching, it is tempting to
speculate that a cytokine normally produced by CD8+ cells
may be response limiting in mice lacking these cells. For
example, this isotype distribution pattern might be predicted
if y interferon were limiting in the f32m-/- mice. This
cytokine is known to be secreted by CD8+ cells as well as
CD4+ cells. It is of interest that our serum antibody data
differ from those reported by Fung-Leung et al. (38) for
vesicular stomatitis virus (VSV) infection of transgenic mice
devoid of CD8+ T cells owing to a disrupted Lyt-2 gene. In
that study, VSV-neutralizing IgM and IgG antibodies were
measured and found to be essentially the same between the
CD8- transgenic mice and wild-type mice. As different
antigens were used to elicit responses in these two studies,
and because total serum antibody titers in these mice prior to
immunization were not reported, direct comparison of the
data is not possible. The possibility is raised that the absence
of P2m limits the antibody response by an undefined mech-
anism not related to the absence of CD8+ cells. Further
studies will be necessary to clarify this issue.
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